These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 4924778)

  • 21. [The effect of aminazine on the excretion of adrenaline noradrenaline, dopamine and dopa in healthy subjects and in the manic phase of manic-depressive psychosis].
    Matlina ESh; Osipova MS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(1):128-31. PubMed ID: 5448719
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of a decarboxylase inhibitor (Ro 4-4602) and L-dopa on inhibited depressions. II. Experimental psychological studies].
    Pohlmeier H; Schön I; Matussek N
    Arzneimittelforschung; 1970 Jul; 20(7):932-3. PubMed ID: 4918920
    [No Abstract]   [Full Text] [Related]  

  • 23. L-dopa plus decarboxylase inhibitor in depression.
    Matussek N; Benkert O; Schneider K; Otten H; Pohlmeier H
    Lancet; 1970 Sep; 2(7674):660-1. PubMed ID: 4195791
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
    Nasrallah HA; Dunner FJ; McCalley-Whitters M; Smith RE
    J Clin Psychiatry; 1986 Feb; 47(2):56-9. PubMed ID: 3003037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lithium and alpha-methyl-p-tyrosine prevent "manic" activity in rodents.
    Davies C; Sanger DJ; Steinberg H; Tomkiewicz M; U'Prichard DC
    Psychopharmacologia; 1974 Apr; 36(3):263-74. PubMed ID: 4152541
    [No Abstract]   [Full Text] [Related]  

  • 26. [L-tryptophan therapy of DOPA psychoses].
    Birkmayer W; Neumayer E
    Nervenarzt; 1972 Feb; 43(2):76-8. PubMed ID: 4501978
    [No Abstract]   [Full Text] [Related]  

  • 27. Parkinsonism and DOPA.
    Cotzias GC; Papavasiliou PS; Gellene R; Aronson RB
    Trans Assoc Am Physicians; 1968; 81():171-83. PubMed ID: 4889342
    [No Abstract]   [Full Text] [Related]  

  • 28. A clinical trial of a-methyl-para-tyrosine in mentally ill patients.
    Charalampous KD; Brown S
    Psychopharmacologia; 1967 Oct; 11(5):422-9. PubMed ID: 4870988
    [No Abstract]   [Full Text] [Related]  

  • 29. [Trial of L-dopa as hypotensive medication in arterial hypertension. Preliminary report].
    Torres Zamora M; García Monterd G; Chávez Domínguez R; Chávez Lara B; Serrano PA
    Arch Inst Cardiol Mex; 1974; 44(2):267-74. PubMed ID: 4599277
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of alpha-methyl-p-tyrosine on 3,4-dihydroxyphenylalanine (DOPA) excretion of hamsters with melanotic melanoma.
    Voorhess ML
    Cancer Res; 1968 Mar; 28(3):452-4. PubMed ID: 5640864
    [No Abstract]   [Full Text] [Related]  

  • 31. Amine precursors and depression.
    Mendels J; Stinnett JL; Burns D; Frazer A
    Arch Gen Psychiatry; 1975 Jan; 32(1):22-30. PubMed ID: 1089400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 33. Catecholamines and memory: enhanced verbal learning during L-DOPA administration.
    Murphy DL; Henry GM
    Psychopharmacologia; 1972; 27(4):319-26. PubMed ID: 4648617
    [No Abstract]   [Full Text] [Related]  

  • 34. The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety.
    McCann UD; Thorne D; Hall M; Popp K; Avery W; Sing H; Thomas M; Belenky G
    Neuropsychopharmacology; 1995 Aug; 13(1):41-52. PubMed ID: 8526970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma dopa responses during stress: dependence on sympathoneural activity and tyrosine hydroxylation.
    Kvetnansky R; Armando I; Weise VK; Holmes C; Fukuhara K; Deka-Starosta A; Kopin IJ; Goldstein DS
    J Pharmacol Exp Ther; 1992 Jun; 261(3):899-909. PubMed ID: 1602395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sleep and behavioral changes possibly reflecting central receptor hypersensitivity following catecholamine synthesis inhibition in man.
    Bunney WE; Kopanda RT; Murphy DL
    Acta Psychiatr Scand; 1977 Sep; 56(3):189-203. PubMed ID: 197795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tryptophan and amitriptyline in the treatment of depression (double blind study)].
    Ayuso Gutiérrez JL; López-Ibor Aliño JL; Montejo Iglesias ML
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1973; 1(3):471-6. PubMed ID: 4585396
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma neutral amino acids in mania and depression: variation during acute and prolonged treatment with L-tryptophan.
    Møller SE; Amdisen A
    Biol Psychiatry; 1979 Feb; 14(1):131-9. PubMed ID: 420897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The switch process from depression to mania: relationship to drugs which alter brain amines.
    Bunney WE; Murphy DL; Goodwin FK; Borge GF
    Lancet; 1970 May; 1(7655):1022-7. PubMed ID: 4191630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.